Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialJAMA Oncol 2023 Mar 09;[EPub Ahead of Print], TC Haddad, VJ Suman, AB D'Assoro, JM Carter, KV Giridhar, BP McMenomy, K Santo, EL Mayer, MS Karuturi, A Morikawa, PK Marcom, CJ Isaacs, SY Oh, AS Clark, IA Mayer, K Keyomarsi, TJ Hobday, PP Peethambaram, CC O'Sullivan, RA Leon-Ferre, MC Liu, JN Ingle, MP Goetz
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.